Introduction
The first description of a syndrome consisting of rheumatoid joint disease in the patients is less active, suggesting that the link between the two is complicclassical rheumatoid arthritis (RA), splenomegaly, and neutropenia was reported in 1924. 1 Felty's ated, and reflects other processes. Felty's syndrome has a poor prognosis, reflecting syndrome (FS) is now recognized to occur in less than 1% of patients with RA, and more commonly increased mortality due to the higher incidence of severe infection, with up to 36% 5-year mortality.4 in those with previously severe forms of the arthropathy. In these individuals with FS there is a greater Most infections documented in FS are due to bacterial pathogens, consistent with an underlying defect in incidence of extra-articular and constitutional manifestations, seropositivity for rheumatoid factors, and neutrophil activity, and the acquired neutropenia is one of the additional main factors predisposing to strong immunogenetic association with HLA DR4.2,3 The degree of splenomegaly varies over time and infection in this subgroup of RA. Abnormalities of neutrophil function may also be found in some extent in individuals with FS; indeed, there is evidence that patients with and without splenomegaly patients.5 The pathogenesis of the neutropenia in FS has not been clearly defined; there is evidence are clinically, immunologically and genetically very similar.2 It is interesting that the pathognomonic for impaired granulopoiesis, increased peripheral destruction, as well as sequestration within the neutropenia of FS is often found at a time when the enlarged spleen.2,6 In general, direct evidence for lenograstim (Granocyte vials at 263 mg/ml or 105 mg/ml, Chugai). 'Full' doses of G-CSF were antibody-or immune-complex-mediated peripheral destruction has been surprisingly hard to substantidefined as the contents of the 300 mg/ml filgrastim or 263 mg/ml lenograstim vials; 'reduced' doses as ate.2,7-9 In addition, FS is associated with a form of T cell lymphocytosis, in which the expanded half (or less) of the full doses (or in the case of lenograstim the 105 mg/ml vial). Follow-up was lymphocytes have a large granular morphology.9-12 This large granular lymphocyte (LGL) syndrome may initially weekly by a specialist nurse practitioner, and at least monthly by medical staff. be defined as large granular lymphocytes present in the peripheral blood at >1×109/l or making up Assessments of the RA were made before and during treatment with G-CSF. The Disease Activity >25% of the total lymphocytes, and it is recognized in about a third of all patients with FS. The T-cell Score (DAS) is a combined index designed to assess disease activity in RA, and a modification of the proliferations in FS may be clonal,13,14 and there is some in vitro evidence to indicate that these CD8+ original DAS index was scored for patients in this study, based on a 28 tender joint count, a 28 swollen T cells inhibit granulopoiesis either directly or through the production of specific cytokines, but the joint count, the patient's global assessment and the erythrocyte sedimentation rate.19 For this modified details are not confirmed.7,9
In managing FS, it may be necessary specifically score, a change of 1.08 is felt to represent a significant improvement or deterioration. Spleen size to treat the haematological manifestations, including the neutropenia. Disease-modifying rheumatoid was monitored in patients using measurements obtained at ultrasound or by clinical examination, agents, including methotrexate may improve the neutropenia, but the response is not consistent. 15 recording the maximal distance below the costal margin. The indications for separately considering other treatments of neutropenia, and with which agents, have
Haematoxylin-and eosin-stained peripheral blood films were examined for the presence of large not been established. Splenectomy has been traditionally advocated, but recurrence of the neutropenia granular lymphocytes. Immunophenotyping of peripheral blood lymphocytes was performed by flow remains a problem for a significant number of patients; moreover, splenectomy is associated with cytometry using a Coulter EPICS counter and a range of commercially-available fluorescent-labelled a further infection risk.4, 15 Recently, interest has focused on haemopoietic monoclonal antibodies. growth factors, including granulocyte colonystimulating factor (G-CSF); the rationale for the use of these agents is that they might counteract an Results impaired production of neutrophils in patients with FS.16 A major difficulty in assessing the value of Eight FS patients with a mean age of 68 years (range 60-74 years) were started on G-CSF. All patients growth factor treatments for patients with FS and severe neutropenia is the lack of reported clinical had disabling arthritic changes, and were positive for rheumatoid factors. In seven patients, recurrent trials,15 although a number of case reports attest to their potential benefits. [16] [17] [18] Due to the location of a infections were the main indication for G-CSF, the foci of infection being the skin, subcutaneous tissues large Rheumatology Centre in this region, it has been possible to follow prospectively the progress of eight and respiratory tract. G-CSF was commenced in two patients with the intention of raising the neutrophil FS patients with severe neutropenia who were commenced on treatment with G-CSF for different count to cover major orthopaedic surgery. Table 1 summarizes these and other relevant demographic reasons. This has allowed us to assess the effectiveness of treatment, the incidence of side-effects, features of the patients, together with the details of haematological indices and LGL counts prior to and the details of dosing regimens. treatment. One patient (GB) was also an insulindependent diabetic. Only one patient was receiving a disease-modifying anti-rheumatic drug during the Methods course of G-CSF ( JD: hydroxychloroquine); three were taking low-dose prednisolone. Patients enrolled into the study all fulfilled the classical criteria for Felty's syndrome of rheumatoid Six patients were commenced on lenograstim initially, two on filgrastim. Dosage was lenograstim arthritis (RA), splenomegaly, and neutropenia (absolute neutrophil count <1×109/l). In addition, these at 263 mg/day, or filgrastim at 300 mg/day. In two patients, 'reduced' doses were given at the start patients had recurrent and severe infections or required joint replacement surgery. G-CSF for subcu-(lenograstim at 105 mg/day or filgrastim at 150 mg/day). Two patients were changed to the taneous injection was available as either filgrastim (Neupogen vials at 300 mg/ml, Amgen/Roche) or alternative G-CSF proprietary preparation soon after starting treatment because of severe side-effects, and therapy the mean counts fell slightly (data not shown), and this was associated with a small reducin these cases 'reduced' doses of the second G-CSF formulation were used initially. Table 2 summarizes tion in spleen size in one of these individuals. The DAS scores were monitored to assess severity the doses of G-CSF used at different times after starting treatment and the side-effects encountered of rheumatoid arthritis, but did not alter significantly or consistently in any patient during G-CSF treatment. during G-CSF treatment.
Five individuals developed significant side-effects This is illustrated in Figure 1 , together with the changes in neutrophil count. In view of concerns during the first 1-2 weeks of G-CSF treatment. Two of these patients, who had been commenced on that lack of change in the composite DAS score during treatment might mask underlying changes in lenograstim (263 mg, initially daily or alternate daily) reported symptoms that included malaise and severe the individual parameters that make up the score, separate analyses of joint tenderness and swelling generalized bone pains, affecting the sternum, back and legs. Both patients ( JP and NB) declined further were plotted, but again this revealed no significant change during treatment with G-CSF. G-CSF injections after one week because of the distressing nature of these side-effects. Of interest, Three individuals had expansions of CD8+ T lymphocytes with a large granular morphology peripheral blood counts taken during the week of treatment showed a temporary reduction of platelet (Table 1 ). Longitudinal studies of lymphocyte subsets before and during G-CSF treatment were conducted numbers to around 100×109/l. 20 Of the remaining three patients who developed by peripheral blood immunophenotyping. In two cases there was no significant change in the levels problems soon after commencing filgrastim G-CSF treatment, one (AM) developed a widespread vasculof the proliferations during G-CSF treatment, but in one patient there was a marked reduction in the itic rash, most prominent over the buttocks, and upper thighs. Changing the G-CSF formulation to level of the LGL expansion (Table 3) . lenograstim in this individual, and starting at a lower dose, did not cause a recurrence of the rash, and enabled the injections of G-CSF to be continued for Discussion over 6 months. The other two patients (GB and IG) reported flu-like symptoms, nausea, sweats, and to G-CSF, an 18 kDa glycoprotein encoded by a gene located on chromosome 17q, has haemopoietic a varying degree, generalized pain in the joints. These symptoms initially persisted in one individual lineage-specific functions, in that it stimulates proliferation and maturation of granulocyte precursors, (IG) despite changing the formulation of G-CSF, and reducing the initial dose, before gradually settling.
and activates mature neutrophils.21 Current clinical indications for recombinant human G-CSF include In the other patient (GB), it became apparent that these symptoms represented occult infection, which mobilization of peripheral blood progenitor cells for transplantation, and management of cytotoxic settled with anti-microbial therapy, allowing the G-CSF injections to be continued without further induced neutropenia, and treatment courses in these situations are usually short and very well tolerated. complication. One patient ( JD), who had been stabilized on filgrastim injections for over 1 year, By contrast, the role and use of long-term G-CSF in severe chronic neutropenia states is less clearly but in whom it was necessary to briefly change to lenograstim, reported the development of troubledefined, although reported for many causes of inherited and acquired neutropenia.22 Felty's syndrome some nausea. She was returned to filgrastim, on which she has remained for a further 2 years without represents a subgroup of RA that is characterized by persisting neutropenia, which is a major factor in complication.
All six patients who were stabilized on G-CSF the increased susceptibility of these patients to recurrent infection. Moreover, the presence of infective injection therapy showed a consistent rise in mean absolute neutrophil counts to values within the range complications in FS has been inversely correlated with endogenous G-CSF production.23 However, 1-4.5×109/l (Table 1 ). In the individuals treated because of recurrent infections, there was a reduction G-CSF, through its actions on myeloid cells and precursors, might be expected to affect the cellular in severity of infective (usually respiratory) episodes, or a clear improvement in the site of main infection, and cytokine mechanisms underlying the inflammatory changes in RA,24 and therefore could exacerbate such as skin ulcers (MT), rheumatoid nodules ( JD), or sites of previous operations (DW). Joint replacethe joint disease.25,26 The aim of this study was to monitor prospectively G-CSF treatment of the neutroments indicated in two patients (IG, MT) were performed without post-operative complications of penia in FS, paying close attention to the frequency of side-effects. sepsis. Mean platelet counts before starting G-CSF treatment varied from low to within normal range These side-effects were more common than expected, and the complications were sufficiently (Table 1) ; in two patients on established G-CSF menced on full doses of G-CSF in the first week, which were associated with distressing side-effects. Despite the frequency of side-effects, it was possible to achieve regular G-CSF treatment in most patients. One patient has been on G-CSF treatment for over 3 years. Neutrophil responses to continued G-CSF treatment were documented in all cases, and associated with reduced rates of severe infection or improvement at the sites of chronic sepsis. It was initially thought that maintenance doses of G-CSF reduced doses at less frequent intervals (twice weekly) may achieve the same clinical benefit, even if the absolute rises in neutrophil counts were smaller severe at some stage in 6/8 patients to warrant either (to 1×109/l). A reduction in platelet count relative stopping the drug and reducing the dose, or switching to baseline values was also documented in several to the alternative proprietary formulation in an patients during the period of G-CSF treatment, but attempt to continue the treatment ( Table 2 ). The main the underlying mechanism is not clear.20 early side-effects included severe nausea, joint pains, There was no evidence using the modified Disease malaise, and skin rashes. These complications have Activity Score (DAS) that long-term G-CSF treatment been reported in other patients, but it is difficult to caused a deterioration of the RA. Four patients on assess the frequency of these side-effects based on established G-CSF treatment generally felt better and individual case reports.25,27 The side-effects found in reported subjective improvement of their joints our study were not confined to filgrastim, the nonduring G-CSF treatment, although the DAS score did glycosylated formulation of G-CSF, which has been not change significantly. Those two patients who considered a theoretical risk since in humans only described severe joint pains and malaise in the first the glycosylated molecule is synthesized.
week after starting G-CSF treatment did not develop Starting the G-CSF treatment at lower doses, and other signs of active arthritis, and the symptoms then gradually increasing the dose to optimize the settled promptly after stopping G-CSF. Concerns have neutrophil response could reduce side-effects. We also been raised about the leukaemogenic risk associwould now recommend commencing all FS patients ated with long-term use of growth factors, although on lower G-CSF doses at the start of treatment (even this was not identified in this study.28 down to a 1/10th full vial two or three times weekly, For one of the patients (GB) there was a reduction then increased after several doses to half a vial, or the of the proportion of large granular lymphocytes in 105 mg/ml lenograstim dose, every other day or daily).
the peripheral blood during G-CSF treatment. At the The two individuals in whom growth factor treatment was stopped but not restarted had both been comstart of treatment this subset of T cells had Immunophenotyping of lymphocytes was performed as described in text. Data are % positivity, except for lymphocyte counts.
